Patent ID: 9180185
Filing Date: 2015-11-10
Classification: A61K,A61P,C07K

Abstract:
1. A method of treating a patient suffering from a HER2-normal cancer wherein the method comprises the co-administration of an antibody which binds to human HER3 in combination with an antibody which binds to human HER2 and which inhibits dimerization of HER2, wherein the antibody which binds to human HER3 comprises a heavy chain variable domain comprising a CDR3H region of SEQ ID NO: 1, a CDR2H region of SEQ ID NO: 2, and a CDR1H region of SEQ ID NO:3, and a light chain variable domain comprising a CDR3L region of SEQ ID NO: 4 a CDR2L region of SEQ ID NO:5, and a CDR1L region of SEQ ID NO:6 or a CDR1L region of SEQ ID NO:7.